10x Genomics Puts Single Cell Analysis Within Reach of All With Low Throughput Gene Expression Kit
April 01 2021 - 8:30AM
10x Genomics, Inc. (Nasdaq: TXG) today announced the launch of its
Chromium Single Cell Gene Expression Low Throughput (LT) Kit, a new
offering designed to put the power of single cell analysis within
the reach of more scientists than ever before. The new LT Kit
reduces the startup cost for a single experiment, enabling a
broader base of scientists to conduct single cell analysis. In
addition, scientists now have the ability to use the 10x Genomics
Cloud to perform a standard analysis of every sample at no
additional cost, accelerating findings in a cost-effective manner.
As a leader in single cell sequencing, 10x Genomics continues to
develop products to accelerate access and affordability for a
broader base of scientists across academia, research institutions,
and pharmaceutical companies. Today’s news gives scientists a range
of options to conduct single cell analysis from their first starter
project of a few hundred cells to standard scale experiments of
thousands to tens of thousands of cells all the way to high
throughput million cell studies with the company’s next-generation
Chromium X instrument, slated for release later this year.
10x Genomics recently started shipping its Single Cell Gene
Expression with CellPlex, making single cell analysis on its
standard kits more affordable. The CellPlex solution allows the
multiplexing of up to 96 samples in a single chip, giving
scientists the ability to drive larger experiments as they scale up
from the LT Kit. CellPlex will also integrate into the company’s
high throughput kits to be released with Chromium X.
“Studying biology at the single cell level is at the core of any
scientist's toolbox to make discoveries for the most pressing
diseases and to advance human health,” said 10x Genomics Co-founder
and Chief Scientific Officer Ben Hindson. “With the 10x Genomics
Low Throughput Gene Expression Kit, we are democratizing single
cell analysis, and we hope it catalyzes a whole new set of
discoveries never imagined before.”
“We are excited that the 10x Genomics Low Throughput kit will
enable faster tech dev by allowing us to pilot and optimize
experimental conditions,” said Joseph Replogle of the Whitehead
Institute for Biomedical Research at MIT. “It will also broaden the
biological applications we can explore, especially working in new
cell and organoid models.”
The Single Cell Gene Expression LT Kit offers several key
features:
- Profiles gene expression for 100 to 1,000 single cells by
barcoding mRNA at the 3’ end, allowing unbiased characterization of
cell types and states
- Combines gene expression analysis with detection of hundreds of
cell surface proteins using oligonucleotide-conjugated antibodies
for cellular phenotyping
- Enables cost-effective optimization of experimental conditions
and sample prep to maximize the design and impact of single cell
experiments
- Follows a ready-to-use, robust workflow with demonstrated
protocols for diverse sample types, including cell lines, primary
cells, and dissociated tissue
The 10x Genomics Single Cell Gene Expression LT Kit is available
now
at https://pages.10xgenomics.com/lt-gene-expression-launch.html,
and CellPlex at https://pages.10xgenomics.com/cellplex.html.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world, including all of the
top 100 global research institutions, as ranked by Nature in 2019,
and all of the top 20 global pharmaceutical companies, as ranked by
2019 research and development spend, and have been cited in over
2,250 research papers on discoveries ranging from oncology to
immunology, and neuroscience. The company’s patent portfolio
comprises more than 1,000 patents and patent applications.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which are
subject to the “safe harbor” created by those sections. All
statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding 10x Genomics product performance,
configuration and capabilities and adoption. These statements are
based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management, and
actual outcomes and results could differ materially from these
statements due to a number of factors, including the potential
impact of the COVID-19 pandemic. Other risks and uncertainties that
could affect 10x Genomics, Inc.’s financial and operating results
and cause actual results to differ materially from those indicated
by the forward-looking statements made in this press release
include those discussed under the captions “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” and elsewhere in the documents 10x Genomics,
Inc. files with the Securities and Exchange Commission from time to
time. Although 10x Genomics, Inc. believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to 10x Genomics, Inc. as of the date hereof,
and 10x Genomics, Inc. disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward- looking statements should not be relied upon as
representing 10x Genomics, Inc.’s views as of any date subsequent
to the date of this press release.
Disclosure Information10x Genomics uses filings
with the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
ContactsMedia:media@10xgenomics.comInvestors:investors@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jul 2023 to Jul 2024